Receptor-Tyrosine-Kinase-Targeted Therapies for Head and Neck Cancer

الملخص EN

Molecular therapeutics for treating epidermal growth factor receptor-(EGFR-) expressing cancers are a specific method for treating cancers compared to general cell loss with standard cytotoxic therapeutics.

However, the finding that resistance to such therapy is common in clinical trials now dampens the initial enthusiasm over this targeted treatment.

Yet an improved molecular understanding of other receptor tyrosine kinases known to be active in cancer has revealed a rich network of cross-talk between receptor pathways with a key finding of common downstream signaling pathways.

Such cross talk may represent a key mechanism for resistance to EGFR-directed therapy.

Here we review the interplay between EGFR and Met and the type 1 insulin-like growth factor receptor (IGF-1R) tyrosine kinases, as well as their contribution to anti-EGFR therapeutic resistance in the context of squamous cell cancer of the head and neck, a tumor known to be primarily driven by EGFR-related oncogenic signals.